ILLUMINA INC
ILMNNASDAQTrading Snapshot
- Day Range
- $277.20 – $294.20
- 52-Week Range
- $94.00 – $309.35
- Volume (shares)
- 2,238,388
- Avg Volume (shares)
- —
- Shares Outstanding
- 151.0M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $4.34B
- Last Q Revenue
- $1.16B
- P/E Ratio
- 53.4
- P/S Ratio
- 9.7x
- EPS (TTM)
- $5.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −3.7%
ILLUMINA INC
ILMN
StockOtter · stockotter.spaceAbout ILLUMINA INC
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Illumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Illumina (ILMN) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insigh
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
Microsoft Corporation was the portfolio's top contributor during the quarter. Suncor Energy outperformed the Index during the quarter. KLA Corporation traded lower during the quarter.
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO, Oct. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference Jefferies Glo
Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?
FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Atlatl Advisers LLC Purchases New Stake in Illumina, Inc. $ILMN
Atlatl Advisers LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ: ILMN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The